Pitch a piece
Write for Anthivera.
A women's-vertical peptide publication looking for evidence-grade work — research syntheses, clinical perspectives, evidence reviews. Tiered honoraria start when Anthivera+ launches in 2026; contributors who publish before launch get retroactive consideration. Light editing, vendor-neutral by policy, your voice intact.
Who reads us
Small list, careful audience.
We're honest about the stage: Anthivera is in year one. Reach is small, intent is high.
Target reader
Women, mostly 35–55, actively researching peptide therapy for perimenopause, libido, recovery, or skin. Editorial voice and topic mix are built around this reader.
Not our reader
Biohacker forums, longevity bros, casual wellness shoppers. We're the careful end of the market.
What they want
Citations, regulatory accuracy, plain language. They open the newsletter to read, not skim.
Why pitch us now
Vertical positioning compounds. Early bylines anchor topic authority before the niche gets crowded.
Formats we publish
Five formats, all sourced.
Research synthesis
A peer-reviewed study (or two) translated for a careful lay reader. State what was studied, in whom, with what effect size and what limits. 1,000–2,000 words.
Clinical perspective
From a credentialed practitioner. What you see in practice, what the evidence supports, where the two diverge. Includes disclosures and credentialing details. 1,200–2,400 words.
Evidence review
State-of-evidence on a specific peptide, intervention, or condition relevant to women's health. Comprehensive citations, dated, with explicit limits. 1,500–3,000 words.
Regulatory analysis
FDA action, compounding rule change, state-level scope-of-practice shift. What changed, who it affects, what readers should watch for. 800–1,800 words.
Cited essay
Personal-but-grounded. Lived experience, observed practice, or longform argument — sourced and disclosed throughout. 1,200–2,500 words.
Topics we're commissioning
Pitches that fit these get prioritized review.
These are the editorial slots we'd green-light fast. Updated quarterly to reflect where our database, our readers, and the regulatory record need the most work.
Updated quarterly
GLP-1 + bone density and muscle in women
Long-term off-target effects of semaglutide and tirzepatide on lean mass. Clinical perspective preferred.
PT-141 (Vyleesi): real-world tolerability
What clinicians are actually seeing post-approval — patient selection, side effects, off-label use. Clinical perspective (distinct from our published PT-141 evidence review).
Sermorelin and tesamorelin in mid-life women
GH-releasing peptides for the perimenopausal panel. State of evidence, comparative safety, where the prescribing window actually sits in 2026. Evidence review.
Compounded GLP-1 alternatives post-shortage (2026)
What 503A and 503B pharmacies can still legally compound after FDA shortage-list changes. Patient-impact framing. Regulatory analysis.
Peptides during pregnancy and lactation
What's known, what's unknown, what's contraindicated. High-value safety reference. Evidence review with conservative defaults.
GHK-Cu in 2026: what new studies changed
Update angle on our published GHK-Cu piece — any new 2025–2026 trials, dosing changes, or formulation findings worth re-cutting the recommendation around. Evidence review (update).
The standards
What every pitch has to meet.
The same standards we apply to our own work. Pitches that hit these get a faster, warmer review.
- Original work, not previously published elsewhere
- Every factual claim cited to a primary source
- Vendor-neutral — no provider name-checking, no commercial advocacy
- Written for women, not retrofitted from a general-audience piece
- No medical recommendations or condition-specific clinical advice
- All commercial relationships, clinical affiliations, and conflicts disclosed upfront
How it works
Pitch, review, draft, publish.
- 01
Pitch
Email a 250-word abstract, an outline, a link to your past work, and any disclosures. We respond to every pitch.
- 02
Review
Editorial review within two weeks. We confirm fit, scope the piece, agree on the angle and length, and set a draft deadline.
- 03
Draft + edit
You draft; we edit lightly — primarily for clarity, sourcing, and disclosure language. Your voice stays your voice.
- 04
Publish
Your piece publishes with full byline, author bio, and a link to your work. Permanent attribution; cited in our future pieces where relevant.
What you get
Tiered honoraria. Byline. Cross-promo. Network.
RETROACTIVE
Honorarium for pre-launch contributors
Pieces published before Anthivera+ launches in 2026 are considered for retroactive honorarium when the budget activates — case by case, not a guaranteed payout. We say so up front so you can decide whether the bet fits.
ANTHIVERA+ TIER
Premium honorarium for premium pieces
Pieces accepted into Anthivera+ Premium — exclusive deep-dives, subscriber-only scorecards, members-only research — earn a higher tier of honorarium. They stay cited in our public work, so attribution still compounds.
BYLINE
Author credit, permanently
Full byline, author bio with a link to your work or practice, attribution that never goes away — even when a piece is updated.
ATTRIBUTION
Cited generously in future work
Your contributions become source material for Anthivera's ongoing reviews. Where your work informs our updates, we cite you by name.
CROSS-PROMO
Your work, amplified
Contributors with their own newsletter, podcast, or practice get featured in our issues where it makes sense. We'd rather lift writers we publish than chase paid placements.
NETWORK
Editorial Partner Network membership
Accepted contributors join the Editorial Partner Network — early access, direct editorial line, first access to the paid affiliate program when Anthivera+ launches.
Recent work
What published bylines look like here.
Three of the most recent pieces. Your byline would sit at the top of one of these.
- skin9 min
Peptides for Skin & Collagen: GHK-Cu and What It Does
GHK-Cu is one of the most-searched skincare peptides. Here's what the research shows for skin, collagen, and aging — and the difference between topical and injectable.
By Anthivera Editorial
- hormone13 min
Peptides for Perimenopause: What the Research Actually Says
A grounded look at peptides discussed for perimenopause — GH-axis peptides, BPC-157, kisspeptin, collagen, GLP-1 — and where the evidence is strong versus preliminary, with the current 2026 regulatory and safety picture.
By Anthivera Editorial
- libido10 min
PT-141 (Bremelanotide) for Women: Libido, Safety, and What to Know
PT-141 / Vyleesi is FDA-approved for low sexual desire in premenopausal women. Here's how it works, what the Phase 3 trials actually showed, and what to know about safety, off-label use, and access.
By Anthivera Editorial
How to pitch
Send a pitch by email.
We don't have a submission form yet — and we like that we don't. A real email, written by you, tells us more than a form would. Include the following in the body:
- Your name, email, and a one-line credential or context
- Pitch title and which format it is (research synthesis, clinical perspective, etc.)
- A 250-word abstract: what the piece will argue, what evidence it leans on, who it's for
- An outline (3–6 bullet points)
- Two links to your past work
- Your peptide-therapy expertise: clinical practice, research background, or audience engagement in this space (one sentence)
- Disclosures in the peptide / telehealth space: provider consultancies, equity stakes, paid advisory roles, or related conflicts
Prefer to hear about new editorial calls first? Drop your email below — we send a short note when a specific topic is open for pitches.
FAQ
Common questions.
- Do you pay contributors?
- Not in Phase 1. Anthivera+ launches in 2026 and pays per-piece honoraria from then forward. Contributors who publish before launch get retroactive consideration when the budget activates. We say so plainly so you can decide.
- Who owns the published piece?
- You retain copyright. Anthivera gets a perpetual, non-exclusive license to publish, update, and cite the piece. You can republish elsewhere after a 90-day exclusivity window, with attribution back to Anthivera.
- Do I have to be a clinician or PhD?
- No. We publish credentialed clinicians and credentialed writers. What matters is sourcing — every claim cited, every conflict disclosed, every limit stated. The byline reflects what you actually are.
- How heavy is the editing?
- Light. We edit primarily for clarity, sourcing strength, and disclosure language. We don't rewrite your voice. If a structural change makes sense, we discuss it before doing it.
- What's the firewall?
- Provider reviews and ratings stay independent. Contributors can't write about a provider they have a commercial relationship with. Editorial decisions never trade on commercial relationships. See our affiliate disclosure for the full picture.